Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NETWORK 7OTHER 2NIH 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Lymphoma, Large B-Cell, Diffuse 8Sarcoma 5Neoplasms 4Lymphoma, Non-Hodgkin 4Immunoproliferative Disorders 3Recurrence 2Osteosarcoma 2Neoplasm Metastasis 2Lymphoproliferative Disorders 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Lymphoma 2Lymphatic Diseases 2Hematologic Diseases 2Sarcoma, Synovial 1Sarcoma, Endometrial Stromal 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neurofibrosarcoma 1Neuroblastoma 1Neoplasms by Histologic Type 1Liposarcoma 1Leiomyosarcoma 1Immune System Diseases 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Fibrosarcoma 1Desmoplastic Small Round Cell Tumor 1Carcinoma, Renal Cell 1Bone Neoplasms 1B-Cell Malignancies 1

Interventions

Doxorubicin 5Dacarbazine 5Trabectedin 3belinostat 2PTC596 2toripalimab 1soblidotin 1rucaparib 1ridaforolimus 1reolysin 1pembrolizumab 1pazopanib 1olaratumab 1futibatinib 1cixutumumab 1cemiplimab 1anlotinib 1Tablets 1TTI-621 1Rosuvastatin Calcium 1PM 01183 1Midazolam 1Injections 1Imatinib Mesylate 1Ifosfamide 1Fluorouracil 1Erlotinib Hydrochloride 1Docetaxel 1Digoxin 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leiomyosarcoma × Ifosfamide × Clear all
NCT06277154 2025-07-24

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

HRYZ Biotech Co.

Phase 2 Recruiting
148 enrolled
GynecologicSarcoma

Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Endometrial Stromal, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡